The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

The Sleep Apnea Devices Market presents robust growth opportunities, especially in regions like North America and Europe where awareness, infrastructure, and reimbursement support are strong. However, ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

SecondwindCPAP, a leading provider of high-quality new and refurbished CPAP and BiPAP machines, today announced its enhanced focus on travel-ready CPAP solutions, empowering individuals with sleep ...

The Apple Hearing and Sleep Apnea features are finally here in Thailand after a year they were announced. Here’s how to use them.

In addition to providing oral appliances, Legacy Dental is committed to educating patients about the importance of sleep ...

Family ENT of Georgetown provides compassionate ear, nose and throat care for children and adults, offering advanced ...

Children's Hospital Los Angeles (CHLA) is launching the first sleep registry in the country for children using Apple Watch as ...

Dr. Charlene E. Gamaldo is a Professor at Johns Hopkins School of Medicine with joint appointments in psychiatry, nursing, anesthesiology, and public health. She serves as Vice Chair for Faculty ...

LunAIRo, Apnimed's second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea Index (AHI) f ...

Shortly after Samsung’s Galaxy Unpacked event in New York, I had the chance to participate in a dedicated Health Immersion ...